Uniqure NV
NASDAQ:QURE
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.78
10.12
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Uniqure NV
Uniqure NV
Total Liabilities & Equity
Uniqure NV
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Uniqure NV
NASDAQ:QURE
|
Total Liabilities & Equity
$645.8m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
18%
|
|
|
Pharming Group NV
AEX:PHARM
|
Total Liabilities & Equity
$425.5m
|
CAGR 3-Years
7%
|
CAGR 5-Years
14%
|
CAGR 10-Years
26%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Total Liabilities & Equity
€106.9m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
argenx SE
XBRU:ARGX
|
Total Liabilities & Equity
$4.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
37%
|
CAGR 10-Years
71%
|
|
|
Merus NV
NASDAQ:MRUS
|
Total Liabilities & Equity
$844.7m
|
CAGR 3-Years
33%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Total Liabilities & Equity
$101.7m
|
CAGR 3-Years
71%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Uniqure NV
Glance View
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
See Also
What is Uniqure NV's Total Liabilities & Equity?
Total Liabilities & Equity
645.8m
USD
Based on the financial report for Sep 30, 2024, Uniqure NV's Total Liabilities & Equity amounts to 645.8m USD.
What is Uniqure NV's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
18%
Over the last year, the Total Liabilities & Equity growth was -26%. The average annual Total Liabilities & Equity growth rates for Uniqure NV have been -6% over the past three years , 6% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet
